<DOC>
	<DOCNO>NCT01001026</DOCNO>
	<brief_summary>The purpose study assess safety effectiveness ( immune response ) license H1N12009 influenza vaccine aboriginal child adult . The study enroll 200 healthy adult ( age 20-59 year ) 75 healthy child ( age 6-35 month ) . Adults receive one dose license H1N1 vaccine child receive two dos license H1N1 vaccine approximately 3 week apart . Study procedures include : medical history , blood sample complete memory aid . Participants involve study related procedure approximately 3 week ( adult ) 6 week ( child ) .</brief_summary>
	<brief_title>Rapid Evaluation Pandemic H1N1 Influenza Vaccine Aboriginal Children Adults</brief_title>
	<detailed_description>During first wave H1N12009 pandemic Canada , person aboriginal background often hospitalize severe infection Canadians . Among First Nations member hospitalization rate 5 time higher national average . Common risk factor young age ( child young adult ) underlie health condition . A high proportion aboriginal adult health condition predispose adverse influenza outcome , include diabetes , asthma , obesity smoking-related lung disease . Aboriginals could benefit substantially timely , effective vaccination pandemic influenza expect among first Canadians offer vaccine available . The vaccine dose recommendation base limited study general population , leave open question whether aboriginal respond satisfactorily recommend dosing . Unique social biological factor among aboriginal could affect response vaccination , reduce protection increase adverse effect . Thus would optimal evaluate safety immunogenicity pandemic vaccine among early aboriginal recipient , inform subsequent vaccination aboriginal group . The objective study two-fold : 1 . To evaluate safety immunogenicity H1N12009 influenza vaccine convenience sample child adults aboriginal background ( First Nations , Metis Inuit ) emphasis subgroup great risk severe disease . 2 . To complete evaluation soon pandemic vaccine become available inform subsequent use vaccine aboriginal population .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Written inform consent provide subject Aboriginal ethnicity ( First Nations , Metis Inuit ) Adults 2059 year age Children 635 month age Allergies egg , thimerosal gentamicin sulphate Lifethreatening reaction previous Flu vaccine Bleeding disorder Pregnancy Receipt blood blood product past 3 month Compromised immune system Chronic illness Previous labconfirmed H1N1/2009 infection</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>vaccine</keyword>
	<keyword>H1N1</keyword>
	<keyword>influenza</keyword>
	<keyword>H1N1 influenza vaccine</keyword>
	<keyword>pandemic</keyword>
</DOC>